期刊文献+

HPLC-MS/MS法测定人血浆中美洛昔康的浓度及药物动力学 被引量:3

Determination of meloxicam in human plasma and its harmacokinetics in healthy volunteers by HPLC-MS/MS
下载PDF
导出
摘要 目的建立HPLC-MS/MS法测定人血浆中美洛昔康(meloxicam)的浓度。方法色谱柱为Phenomenex Luna C18(150 mm×4.6 mm,5μm),流动相为乙腈-20 mmol·L-1醋酸铵水溶液(水中含体积分数为0.2%的甲酸)(体积比为70∶30),提取剂为乙酸乙酯-异丙醇(体积比为9∶1),内标物为吡罗昔康,离子源为ESI,流速为0.4 m L·min-1,柱温为30℃。结果美洛昔康线性为0.1~40.0μg·L-1(r=0.993 1),定量下限为0.1μg·L-1,日间和日内精密度RSD均小于11.7%,提取回收率在83.4%~87.1%之间。20名健康受试者背部涂抹美洛昔康凝胶剂后,其主要药物动力学参数为:ρmax=(18.7±9.3)μg·L-1,tmax=(60.0±24.7)h,t1/2=(59.4±27.3)h,AUC0→t=(2 105.9±1 573.4)μg·h·L-1,AUC0→∞(2 297.1±1 734.7)μg·h·L-1。结论本方法适用于测定美洛昔康在人血浆中的浓度。 Objective To develop an HPLC-M S/M S method for determining the concentration of meloxicam in human phasma.Methods Separation was achieved on a reversed-phase C18 column with a mobile phase of acetonitrile-0.2%(φ) FA in water with 20 mmol·L-1ammonium acetate(V ∶ V = 7 ∶ 30).Ethyl acetate-isopropyl alcohol was used as extraction agent.The flow rate was 0.4 m L·min-1and the column temperature was 30 ℃.Piroxicam was used as an internal standard.Results The calibration curve of meloxicam was linear in the concentration ranges of 0.1-40.0 μg·L-1(r = 0.993 1).The lower limit of quantification was0.1 μg·L-1.The RSDs of inter-and intra-day were less than 11.7% and the average recovery of meloxicam was from 83.4% to 87.1%.The main pharmacokinetics parameters of meloxivam were as follow s:ρmax(18.7 ± 9.3) ng·m L-1,tmax(60.0 ± 24.7) h,t1/2(59.4 ± 27.3) h,AUC0→t(2 105.9 ± 1 573.4) μg·h·L-1,AUC0→∞(2 297.1 ± 1 734.7) μg·h·L-1.Conclusions This method is simple,quick with good reproducibility,and was suitable for determination of meloxicam in human plasma.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2014年第12期993-997,共5页 Journal of Shenyang Pharmaceutical University
关键词 美洛昔康 血浆 药物动力学 高效液相色谱-质谱联用 meloxicam plasma pharmacokinetics HPLC-MS/MS
  • 相关文献

参考文献10

二级参考文献60

  • 1温预关,蔡素华,陈国中,陈伟家.高效液相色谱法测定人血浆中塞来昔布的浓度[J].中国医院药学杂志,2004,24(10):602-604. 被引量:11
  • 2戈升荣,安富荣,曹惠明.美洛昔康片溶出度考察及其体内外相关性[J].中国医院药学杂志,2004,24(11):687-689. 被引量:9
  • 3Turck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxiearn[J]. Drug Res, 1997, 47(1):253. 被引量:1
  • 4Schmid J, Bush U, Heinzel G, et al. Meloxicam pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects[J]. Drug Metab Dispos, 1995, 23(11):1206. 被引量:1
  • 5许禄,化学计量学方法,1995年 被引量:1
  • 6萧参,中国药学杂志,1993年,28卷,425页 被引量:1
  • 710 Engelhardt G,Homma D,Schnitzler C.Meloxicam:a potent inhibitor of adjuvant arthritis in the Levis rat[J].Inflamm Res,1995,44:548. 被引量:1
  • 8Mathews KA,Pettifer G,Foster R,et al .Safety and efficacy of preoperative administration of meloxicam,compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery[J] .Am J Vet Res,2001,62 (6):882. 被引量:1
  • 9Tsubouchi Y,Mukai S,Kawahito Y,et al.Meloxicam inhibits the growth of non-small cell lung cancer[J].Anticancer Res,2000,20 (5A):2 867. 被引量:1
  • 10Hussey HJ ,Tisdale MJ .Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model[J] .Iht J Cancer,2000,87(1):95. 被引量:1

共引文献597

同被引文献24

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部